Table 2 Presence of scored elements in request forms from visited Belgian laboratories versus elements required by guidelines/standards
Element | Present for tissue testing | Present for liquid biopsy testing | Required by Belgian standards [13,15,16,20] | Required by international guidelines [41] |
|---|---|---|---|---|
Request forms | N = 4 | N = 4 | ||
Accessibility and design | ||||
Molecular pathology dedicated form | 4 (100%) | 1 (25%) | ||
Lung cancer dedicated form | 0 (0%) | 0 (0%) | ||
Request available online | 4 (100%) | 4 (100%) | ||
Testing technique specified | 4 (100%) | 3 (75%) | ||
Online: summary of test methodology | 2 (50%) | 1 (25%) | ||
Online: indications for testing | 2 (50%) | 3 (75%) | ✓ | |
Online: recipient | 4 (100%) | 4 (100%) | ✓ | |
Online: transport medium | 4 (100%) | NA | ✓ | |
Online: max delay for transport | NA | 4 (100%) | ✓ | |
Online: storage | 4 (100%) | 4 (100%) | ✓ | |
Digital storage completed forms | 3 (75%) | 3 (75%) | ||
Administrative elements | ||||
Prescriber: name | 4 (100%) | 4 (100%) | ✓ | ✓ |
Prescriber: address | 2 (50%) | 2 (50%) | ✓ | ✓ |
Prescriber: RIZIV number or equivalent | 4 (100%) | 4 (100%) | ✓ | ✓ |
Prescriber: department | 1 (25%) | 1 (25%) | ✓ | |
Reimbursement info | 1 (25%) | 2 (50%) | ||
General lab address | 4 (100%) | 4 (100%) | ✓ | |
Contact person in lab | 1 (25%) | 2 (50%) | ||
Patient characteristics | ||||
Patient: name | 4 (100%) | 4 (100%) | ✓ | ✓ |
Patient: DOB | 4 (100%) | 4 (100%) | ✓ | ✓ |
Patient: gender | 4 (100%) | 4 (100%) | ✓ | ✓ |
Patient: address | 4 (100%) | 4 (100%) | ✓ | ✓ |
Patient: internal hospital ref | 4 (100% | 4 (100%) | ✓ | ✓ |
Relevant patient history | 4 (100%) | 2 (50%) | ✓ | ✓ |
Histology of tumor | 2 (50%) | 2 (50%) | ✓ | ✓ |
Primary diagnosis | 1 (25%) | 3 (75%) | ✓ | |
Previous tests performed | 3 (75%) | 3 (75%) | ✓ | |
Original activating mutation | 1 (25%) | 2 (50%) | ✓ | |
Previous therapies (type) | 4 (0%) | 1 (25%) | ✓ | |
Previous therapies (time) | 0 (0%) | 0 (0%) | ||
Progression/not | 3 (75%) | 3 (75%) | ✓ | |
Progression type | 1 (25%) | 2 (50%) | ||
Progression time | 0 (0%) | 0 (0%) | ||
Location primary tumor | 3 (75%) | 3 (75%) | ||
Tumor stage | 3 (75%) | 3 (75%) | ✓ | |
Reason for testing | 0 (0%) | 1 (25%) | ✓ | ✓ |
Sample characteristics | ||||
Sample type | 4 (100%) | 4 (100%) | ✓ | ✓ |
Number of slides/blocks/tubes | 3 (75%) | 4 (100%) | ||
Fixative | 4 (100%) | NA | ||
Fixation time | 4 (100%) | NA | ||
Specification of total blood/plasma | NA | 0 (0%) | ||
Type of collection tube | NA | 3 (75%) | ||
Date of sample collection | NA | 3 (75%) | ✓ | |
Time of sample collection | NA | 3 (75%) | ✓ | |